Efficacy of a nasal spray containing Iota-Carrageenan in the prophylaxis of COVID-19 in hospital personnel dedicated to patients care with COVID-19 disease A pragmatic multicenter, randomized, double-blind, placebo-controlled trial (CARR-COV-02)

Introduction

A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first identified in December 2019 as the cause of a respiratory illness designated Coronavirus disease 2019, or COVID-19. Current available evidence shows that COVID-19 virus is transmitted between people through close contact and droplets. Being in close contact with infected individuals is therefore a risk factor to contract COVID19. Unvaccinated health care providers, who are in close contact with COVID-19 patient are therefore at an increased risk for COVID19. This inevitably places unvaccinated health and other hospital workers at a high risk of infection. Recent COVID19 vaccine developments have shown a high efficacy at preventing COVID19 (1,2), and vaccination rate among healthcare workers in high income countries has grown steadily over the first quarter of 2020 (3-6). Nevertheless, vaccine production challenges, distribution delays and global vaccine access have once again highlighted global inequality. The need to develop additional low cost interventions to mitigate the risk of contracting COVID19 among unvaccinated healthcare providers in particularly important for the global South, whore vaccination rate among healthcare providers remains low. The existence of a prophylactic intervention against this disease (except for vaccines already available) remains unknown.

Iota-carrageenan -a sulfated polysaccharide found in some species of red seaweed (Chondrus crispus)-has demonstrated antiviral activity against respiratory and other viruses in cell culture and in animal models.(7-10) Iota-carrageenan inhibits viruses based on its interaction with the surface of viral particles, thus preventing them from entering cells and trapping the viral particles released from the infected cells. In vitro and in vivo studies have demonstrated the effectiveness of Iota-Carrageenan against several respiratory viruses such as HRV, influenza A and common cold Coronavirus. Carrageenan is generally recognized as safe for use in food and topical applications.

Because the primary site of infection and replication of most cold-causing viruses is the nasal mucosa, it has been hypothesized that early and targeted treatment of the nasal mucosa with Iota-Carrageenan may block viral entry on that level and interfere locally with the propagation of viral replication.

In three randomized clinical trials (two in adults and one in children) that compared Iota-Carrageenan nasal spray with saline solution (placebo) there were strong indications of efficacy, including significantly reduced cold symptoms;(11) positive effects on symptoms in patients in whom less co-medication or no co-medication was used;(12) significantly reduced viral loads;(11-13) and faster reduction of common cold symptoms.(12-13) Treatments were safe and well tolerated.(11-13) In cell culture Iota-Carrageenan has demonstrated antiviral activity against SARS-CoV-2 virus (14,15) and SARSCoV-2 Spike Pseudotyped Lentivirus (SSPL).(16) Taking into account that the concentrations found to be active in vitro against SARS-CoV-2 may be easily achieved by the application of nasal sprays already marketed in several countries,(14) and that during the first days of disease the virus is localized mainly in the nasal cavity and the nasopharynx,(17) we hypothesized that a nasal spray with Iota-Carrageenan could potentially be used as preexposure and during exposure prophylaxis, to prevent symptomatic infection in health workers at high risk of COVID19 infection.

Methods

Results

From July 24, 2020, to December 20, 2020, a total of 400 hospital workers were enrolled and underwent randomization at 10 hospitals in Argentina.

Six participants were excluded from the final analysis because they had symptoms suggestive of COVID-19 at the time of randomization. Of the remaining 394 participants, 196 had been assigned to receive Iota-Carrageenan and 198 to receive placebo.

Thirteen individuals in Iota-Carrageenan group and 14 in placebo group withdrew consent before day 21 and did not provide information about their health status. The mean age of participants was 38.5±9 years old, and 75.1% were female gender (Table 1).

Forty three participants underwent a PCR test for presenting symptoms compatible with COVID-19 (Table 2), 31 were negative (7·6% in the Iota-Carrageenan group and 8.6% in the placebo group; p= 0·8).

Overall, new COVID-19 (symptomatic with PCR-confirmed) developed in 12 of 394 participants (3.04%) during the 21 days of follow-up (Table 2).

The incidence of COVID-19 differs significantly between those receiving the nasal spray with Iota-Carrageenan (2 of 196 [1·0 %]) and those receiving placebo (10 of 198 [5·0 %]) (Odds Ratio 0.19 (95% confidence interval 0.05 to 0.77; p=0.03). Business day losses censored at day 21 were lower in I-C group (0.5% and 2.0%; p< 0.0001). In sensitivity analysis in which we removed from our analyses individuals who presented symptoms before 7 days after randomization, the risk reduction was 95% (95% CI, 6.0% to 99.7%), p= 0.04. OR: 0.05 (95% CI, 0.003 to 0.9), p=0.04.

Days off work in placebo group compared to I-C were 1.6% days / person (95% CI, 1.0 to 2.2); p <0.0001

In the Iota-Carrageenan group and placebo group, 17.3% and 15.2%, respectively, reported at least one adverse effect (p = 0.5)

Discussion

The results of this study show that the Iota-Carrageenan nasal spray is safe and effective to prevent COVID-19 disease in hospital workers providing care for COVID-19 patients. In our study we identified a risk reduction greater than 80%. This finding is particularly relevant as until now the only prophylactic interventions with demonstrated efficacy are vaccines who are not yet accessible worldwide. In facts, vaccination rates among healthcare workers remain particularly low, specially in the global south.

There has been growing interest in the potential efficacy of drugs with demonstrated in vitro efficacy. During the early days of the COVID-19 pandemic, there was an increased attention to the use of hydroxychloroquine, an agent that was active in vitro but did not prevent COVID-19 when used as pre or postexposure prophylaxis(18-20). With at least two registered clinical trials as of February 2021 (Argentina and Austria), Iota-Carrageenan is being proposed as a potential efficacious prophylactic drug. The nasal spray with Iota-Carrageenan has already shown clinical efficacy in diseases of the upper airways produced by viruses against which Iota-Carrageenan had demonstrated efficacy in vitro. Additionally, Iota-Carrageenan’s in vitro efficacy was shown in vitro concentrations equal to and up to 100 times lower than those estimated to be reached in the nasal cavity with the use of sprays available in different countries with standard dosages. We have recently repeated the in vitro study of the effect of carrageenan spray on SARS-COV-2 infection in cultures of a human respiratory epithelium cell line (Calu-3) observing the same inhibitory effect as in Vero cells (submitted).

Our study have some limitations. First, we included apparently healthy individuals without confirmation by PCR test. Second, those who remained asymptomatic were also not tested. Third, we do not know the exposure dose of each participant, although, the number of active principle and placebos administered in each participating center were identical. The devastating urgency of the COVID-19 pandemic requires a simple and pragmatic design trial with the ability to give, in this context, a quick and efficient answer. This is particularly important considering that health providers are overworked and extremely busy, and a higher burden associated with completing numerous data would have resulted in low study compliance.

Our study has also a number of strengths. First, we chose healthcare and other hospital workers to participate in this research as a simple and easy-to-follow model. Second, enrollment took place during a high rate of community transmission in Argentina, therefore, our participants were also exposed outside the hospital. Third, and following the pragmatic nature of this randomized controlled clinical trial and according to the regulations established by the Nation Ministry of Health, we performed only one PCR test between 48 and 72 hours after the onset of symptoms, assuming that a negative first test may not have been enough, nor we have carried out antibody dosages to confirm the disease. Finally, a small number of individuals were lost to follow up (6.8%). In sensitivity analysis where it was hypothesized that the 13 lost individuals from the Iota-Carrageenan group were infected, and that the 14 lost individuals from the placebo group were not infected, no differences were found in infection rates of both groups (p= 0.3).

Conclusions

The nasal spray with I-C showed significant efficacy in preventing SARS-Cov-2 infection in personnel dedicated to care patients with Covid-19 disease. This finding should be replicated in future clinical trials.

Funding

The study did not received support for hospitals, staff or patients involved. Publication and administrative costs were supported by: Programa de articulación y fortalecimiento federal de las capacidades en ciencia y tecnología COVID-19, Proyecto CABA 20. Ministerio de Ciencia, Tecnología e Innovación, Argentina. Laboratorio Pablo Cassará free provided the drug and placebo samples.

Author contributions

JMF, ML, AD, LPF were responsible for the study concept, design, acquisition of data, verification of the underlying data and drafting the manuscript. ML and AD performed statistical analyses. RPG and GS participated in data interpretation, writing the manuscript and agreed on the decision to publish. All authors reviewed, critically revised and approved the final version of the manuscript.

Conflict of Interest

JMF and ML reports personal fees from Laboratorio Pablo Cassará, outside the submitted work.

Clinical trials registration NCT04521322